Integrum welcomes Scott Flora as full board member
Mölndal, Sweden – October 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora was recently elected as full member of the company’s board at the annual general meeting.
Mr. Flora was appointed as Adjunct Board Member in May 2023. At the annual general meeting on September 27, he was elected full member of the board together with Rickard Brånemark, Andrew Christensen, Bengt Sjöholm, Karin Wingstrand, Patric Lindgren, and Cecilia Wikström, who were all re-elected.
“We are glad to welcome Scott Flora as a full member to the board of Integrum. Mr. Flora has already been active in strategic discussions and decision-making, contributing with invaluable insights and knowledge about our core market. Welcoming Mr. Flora is yet another step reflecting Integrum’s trajectory toward becoming an international actor in orthopaedic solutions,” said Bengt Sjöholm, chairman of the board at Integrum.
Scott Flora serves concurrently as chairman of the Board at Palliare Ltd and New View Surgical, and as board member at CytoVeris and Origami Surgical. He has previous experience as board member from Invuity (acquired by Stryker), MAKO Surgical, and Tengion. Mr. Flora is active as Strategic Advisor to CareSyntax, MiCarePath, and Integrum. Furthermore, he has over 40 years of experience from C-suite leadership positions in global companies, including Invuity, Conventus Orthopaedics, OmniGuide Surgical, and Smith & Nephew Orthopedics.
For more information please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Bengt Sjöholm, Chairman of the Board
Phone: + 46 (0) 70 531 38 11
E-mail: bengt.sjoholm@bsjab.se
Certified Adviser
Erik Penser Bank is Certified Adviser.
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.